# Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-052)

> **NCT02335424** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 374 (actual)

## Conditions studied

- Urothelial Cancer

## Interventions

- **BIOLOGICAL:** pembrolizumab

## Key facts

- **NCT ID:** NCT02335424
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02-24
- **Primary completion:** 2018-06-19
- **Final completion:** 2022-02-18
- **Target enrollment:** 374 (ACTUAL)
- **Last updated:** 2023-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02335424

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02335424, "Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-052)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02335424. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*